Summary
Abzena Plc (Abzena), formerly Polytherics Group Limited is a biopharmaceutical company that offers complementary services and technologies to research and development organizations. The company offers proprietary technologies and services for the design and development of biopharmaceuticals and protein based medicines. Its services and technologies address research and development issues to enable the development of biopharmaceutical products. Abzena offer services such as immunogenicity assessment, antibody and protein engineering, optimization of pharmacokinetics, cell line development, process development, GMP manufacturing and manufacturing of small molecules. The company offers its services to biopharmaceutical companies, public and private biotech companies and academic groups. It has its presence in the UK and the US. Abzena is headquartered in Cambridge, the UK.
Abzena Plc (ABZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Abzena Plc, Medical Devices Deals, 2010 to YTD 2016 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
Abzena Raises Funds through Venture Financing 16
PolyTherics Secures US$3.5 Million In Series B Financing 18
PolyTherics Raises US$4.72 Million In Venture Financing 19
Partnerships 20
Abzena Enters into Agreement with Apitope 20
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 21
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 23
PolyTherics Extends Agreement With MacroGenics To Produce Antibody Drug Conjugates 24
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 25
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 26
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 27
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 28
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 29
Antitope Enters Into Research Agreement With NeuroPhage Pharma 30
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 31
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 32
Antitope Enters Into Research Collaboration With Therapure Biopharma 33
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 34
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 35
Antitope Enters Into Co-Development Agreement With IMMIH 36
Antitope Enters Into Research Collaboration With NasVax 37
PolyTherics Enters Into Drug Development Agreement With Critical Pharma 38
PolyTherics Enters Into Co-Development Agreement With MacroGenics 39
PolyTherics Enters Into Collaboration With University College London 40
Antitope Enters Into Research Agreement With Ablynx For Nanobodies 41
Antitope Enters Into Research Collaboration With PIKAMAB 42
Faron Pharma Enters Into Co-Development Agreement With Antitope 43
Antitope Enters Into Research Agreement With Cantab BioPharma 44
PolyTherics Enters Into Research Collaboration With Zealand Pharma 45
Antitope Enters Into Research Agreement With Emory University 46
PolyTherics Enters Into Co-Development Agreement With Cantab 47
Antitope Enters Into Research Agreement With ANRS, INSERM, And Baylor Research Institute 48
Licensing Agreements 50
Abzena Enters into Licensing Agreement for Thiobridge ADC Linker Technology 50
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 51
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 52
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 53
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 54
Nuron Biotech Exercises Option Licensing Agreement With PolyTherics 55
Equity Offering 56
Abzena Raises USD31.8 Million in Private Placement of Shares 56
Abzena Completes IPO 58
Acquisition 60
Abzena Acquires The Chemistry Research Solution for USD15 Million 60
Abzena Acquires PacificGMP 61
PolyTherics Acquires Antitope For US$20.7 Million 63
Abzena Plc - Key Competitors 64
Key Employees 65
Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
List of Tables
Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Abzena Plc, Deals By Therapy Area, 2010 to YTD 2016 10
Abzena Plc, Medical Devices Deals, 2010 to YTD 2016 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Abzena Raises Funds through Venture Financing 16
PolyTherics Secures US$3.5 Million In Series B Financing 18
PolyTherics Raises US$4.72 Million In Venture Financing 19
Abzena Enters into Agreement with Apitope 20
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 21
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 23
PolyTherics Extends Agreement With MacroGenics To Produce Antibody Drug Conjugates 24
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 25
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 26
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 27
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 28
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 29
Antitope Enters Into Research Agreement With NeuroPhage Pharma 30
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 31
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 32
Antitope Enters Into Research Collaboration With Therapure Biopharma 33
Antitope Enters Into Co-Development Agreement With Kolltan Pharma 34
Antitope Enters Into Co-Development Agreement With The University Of North Carolina 35
Antitope Enters Into Co-Development Agreement With IMMIH 36
Antitope Enters Into Research Collaboration With NasVax 37
PolyTherics Enters Into Drug Development Agreement With Critical Pharma 38
PolyTherics Enters Into Co-Development Agreement With MacroGenics 39
PolyTherics Enters Into Collaboration With University College London 40
Antitope Enters Into Research Agreement With Ablynx For Nanobodies 41
Antitope Enters Into Research Collaboration With PIKAMAB 42
Faron Pharma Enters Into Co-Development Agreement With Antitope 43
Antitope Enters Into Research Agreement With Cantab BioPharma 44
PolyTherics Enters Into Research Collaboration With Zealand Pharma 45
Antitope Enters Into Research Agreement With Emory University 46
PolyTherics Enters Into Co-Development Agreement With Cantab 47
Antitope Enters Into Research Agreement With ANRS, INSERM, And Baylor Research Institute 48
Abzena Enters into Licensing Agreement for Thiobridge ADC Linker Technology 50
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 51
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 52
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 53
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 54
Nuron Biotech Exercises Option Licensing Agreement With PolyTherics 55
Abzena Raises USD31.8 Million in Private Placement of Shares 56
Abzena Completes IPO 58
Abzena Acquires The Chemistry Research Solution for USD15 Million 60
Abzena Acquires PacificGMP 61
PolyTherics Acquires Antitope For US$20.7 Million 63
Abzena Plc, Key Competitors 64
Abzena Plc, Key Employees 65
Abzena Plc, Subsidiaries 66
List of Figures
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 7
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 10
Abzena Plc, Medical Devices Deals, 2010 to YTD 2016 11
